ReviewFrontiers in cardiovascular medicine2022
Evidence for the Benefits of Melatonin in Cardiovascular Disease.
Review in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it, 111 citations in OpenAlex.
- Pooled it
- Melatonin administered postoperatively lowers oxidative stress and inflammation and significantly recovers heart function in patients undergoing CABG surgery.European journal of medical research · 2025Trial
- Rest-activity rhythms predict time to hospitalizations and emergency department visits among participants in a randomized control of adults with heart failure and insomnia.Sleep medicine · 2023Trial
- Essential Hypertension and Oxidative Stress: Novel Future Perspectives.International journal of molecular sciences · 2022Trial
- Atrioventricular Block Potentially Associated with Melatonin Supplementation: A Case Report and Systematic Review of Cardiac Rhythm Adverse Events.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Melatonin for age-related vascular diseases: mechanistic rationale, translational barriers, and clinical prospects.Molecular biology reports · 2026Review
- Melatonin supplementation, hyperprolactinemia, and incident heart failure: A proposed prolactin-mediated pathway for cardiovascular risk.World journal of experimental medicine · 2026Review
- Repurposing melatonin for its potential roles in gastrointestinal cancers: highlighting the molecular mechanisms.Cancer cell international · 2026Review
- Prenatal Melatonin Modulates Cardiovascular Function and Oxidative Stress in Guinea Pig Neonates Under Normoxic and Hypoxic Gestation.Antioxidants (Basel, Switzerland) · 2026Article
- Hypoxia, ROS, and HIF Signaling in I/R Injury: Implications and Future Prospects.Antioxidants (Basel, Switzerland) · 2026Review
- The MicroRNAs-STAT3-cyclophilin D-cell apoptosis axis: a novel pathway for phosphocreatine treatment in heart disease.Journal of molecular histology · 2026Review
- From Earth to orbit: cardiovascular innovation diffusion to space medicine - an updated review incorporating a novel predictive modeling framework.Frontiers in physiology · 2026Article
- A review on fueling recovery: the role of metabolic modulation in non-obstructive myocardial stunning.European journal of medical research · 2025Review
- Rethinking Melatonin Dosing: Safety and Efficacy at Higher-than-Usual Levels in Aged Patients with Sleep Disturbances and Comorbidities.Brain sciences · 2025Article
- Circadian Rhythm Disruptions and Cardiovascular Disease Risk: The Special Role of Melatonin.Current issues in molecular biology · 2025Review
- Protective Effect of Melatonin Against Bisphenol A Toxicity.International journal of molecular sciences · 2025Review
- Dark-phase melatonin administration does not reduce blood pressure but induces changes in parameters related to the control of the cardiovascular system in spontaneously hypertensive rats.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Sleep disorders impact hormonal regulation: unravelling the relationship among sleep disorders, hormones and metabolic diseases.Diabetology & metabolic syndrome · 2025Review
- Bidirectional Crosstalk Between Sleep and Pulmonary Arterial Hypertension.bioRxiv : the preprint server for biology · 2025Article
- Melatonin and the Skin: Current Progress and Perspectives for Human Health.The Journal of investigative dermatology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pineal gland is a neuroendocrine gland which produces melatonin, a neuroendocrine hormone with critical physiological roles in the circadian rhythm and sleep-wake cycle. Melatonin has been shown to possess anti-oxidant activity and neuroprotective properties. Numerous studies have shown that melatonin has significant functions in cardiovascular disease, and may have anti-aging properties. The ability of melatonin to decrease primary hypertension needs to be more extensively evaluated. Melatonin has shown significant benefits in reducing cardiac pathology, and preventing the death of cardiac muscle in response to ischemia-reperfusion in rodent species. Moreover, melatonin may also prevent the hypertrophy of the heart muscle under some circumstances, which in turn would lessen the development of heart failure. Several currently used conventional drugs show cardiotoxicity as an adverse effect. Recent rodent studies have shown that melatonin acts as an anti-oxidant and is effective in suppressing heart damage mediated by pharmacologic drugs. Therefore, melatonin has been shown to have cardioprotective activity in multiple animal and human studies. Herein, we summarize the most established benefits of melatonin in the cardiovascular system with a focus on the molecular mechanisms of action.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.